Loading...

Xbrane Biopharma

OM:XBRANE BTA
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XBRANE BTA
OM
SEK371M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
XBRANE BTA Share Price and Events
7 Day Returns
13.7%
OM:XBRANE BTA
-1.8%
SE Biotechs
0.9%
SE Market
1 Year Returns
-
OM:XBRANE BTA
35.2%
SE Biotechs
6.5%
SE Market
XBRANE BTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Xbrane Biopharma (XBRANE BTA) 13.7% - - - - -
SE Biotechs -1.8% 0.9% 5.8% 35.2% 74% 148%
SE Market 0.9% 2.5% 11.8% 6.5% 14% 25.4%
1 Year Return vs Industry and Market
  • No trading data on XBRANE BTA.
  • No trading data on XBRANE BTA.
Price Volatility
XBRANE BTA
Industry
5yr Volatility vs Market

XBRANE BTA Value

 Is Xbrane Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Xbrane Biopharma. This is due to cash flow or dividend data being unavailable. The share price is SEK43.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Xbrane Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Xbrane Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:XBRANE BTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-2.13
OM:XBRANE Share Price ** OM (2019-04-12) in SEK SEK44.7
Sweden Biotechs Industry PE Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 31.21x
Sweden Market PE Ratio Median Figure of 323 Publicly-Listed Companies 17.04x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Xbrane Biopharma.

OM:XBRANE BTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:XBRANE Share Price ÷ EPS (both in SEK)

= 44.7 ÷ -2.13

-20.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xbrane Biopharma is loss making, we can't compare its value to the SE Biotechs industry average.
  • Xbrane Biopharma is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Xbrane Biopharma's expected growth come at a high price?
Raw Data
OM:XBRANE BTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-24.7%per year
Sweden Biotechs Industry PEG Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 1.83x
Sweden Market PEG Ratio Median Figure of 233 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Xbrane Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Xbrane Biopharma's assets?
Raw Data
OM:XBRANE BTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK13.12
OM:XBRANE Share Price * OM (2019-04-12) in SEK SEK44.7
Sweden Biotechs Industry PB Ratio Median Figure of 41 Publicly-Listed Biotechs Companies 4.14x
Sweden Market PB Ratio Median Figure of 566 Publicly-Listed Companies 2.51x
OM:XBRANE BTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:XBRANE Share Price ÷ Book Value per Share (both in SEK)

= 44.7 ÷ 13.12

3.41x

* Primary Listing of Xbrane Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xbrane Biopharma is good value based on assets compared to the SE Biotechs industry average.
X
Value checks
We assess Xbrane Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Xbrane Biopharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XBRANE BTA Future Performance

 How is Xbrane Biopharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-24.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Xbrane Biopharma expected to grow at an attractive rate?
  • Unable to compare Xbrane Biopharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Xbrane Biopharma's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.
  • Xbrane Biopharma's revenue growth is expected to exceed the Sweden market average.
Annual Growth Rates Comparison
Raw Data
OM:XBRANE BTA Future Growth Rates Data Sources
Data Point Source Value (per year)
OM:XBRANE BTA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -24.7%
OM:XBRANE BTA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 59.7%
Sweden Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.5%
Sweden Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.9%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 9.1%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:XBRANE BTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:XBRANE BTA Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 183 -60 -74 1
2020-12-31 47 -49 -144 2
2019-12-31 30 -172 -117 2
OM:XBRANE BTA Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 20 47 -13
2018-09-30 25 -4 0
2018-06-30 23 -47 -69
2018-03-31 23 -36 -45
2017-12-31 21 -37 -45
2017-09-30 11 -35 -35
2017-06-30 11 -39 -34
2017-03-31 6 -41 -31
2016-12-31 -39 -28
2016-09-30 0 -37 -24
2016-06-30 0 -27 -19
2016-03-31 1 -19 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Xbrane Biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Xbrane Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:XBRANE BTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Xbrane Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:XBRANE BTA Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -11.62 -11.62 -11.62 1.00
2020-12-31 -18.30 -7.58 -29.03 2.00
2019-12-31 -16.38 -13.63 -19.13 2.00
OM:XBRANE BTA Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -2.13
2018-09-30 0.00
2018-06-30 -11.34
2018-03-31 -7.88
2017-12-31 -8.28
2017-09-30 -8.45
2017-06-30 -9.18
2017-03-31 -6.49
2016-12-31 -6.16
2016-09-30 -4.90
2016-06-30 -4.44
2016-03-31 -6.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Xbrane Biopharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Xbrane Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Xbrane Biopharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XBRANE BTA Past Performance

  How has Xbrane Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Xbrane Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Xbrane Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Xbrane Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Xbrane Biopharma's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Xbrane Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Xbrane Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:XBRANE BTA Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 20.49 -13.24 24.28 85.83
2018-09-30 25.12 0.03 21.89 77.83
2018-06-30 22.64 -69.16 15.48 72.38
2018-03-31 22.55 -45.13 13.89 50.33
2017-12-31 20.77 -44.94 12.95 37.98
2017-09-30 11.24 -34.51 9.76 30.29
2017-06-30 11.28 -34.45 9.78 30.51
2017-03-31 5.99 -30.96 6.24 31.77
2016-12-31 -27.77 8.40 23.86
2016-09-30 0.12 -24.36 10.89 14.01
2016-06-30 0.25 -19.44 12.82 7.18
2016-03-31 1.17 -16.29 14.17
2015-12-31 0.43 -11.84 10.77
2015-09-30 1.64 -7.83 9.55
2014-12-31 1.50 -2.57 4.02
2013-12-31 0.22 -2.11 2.23
2012-12-31 0.99 -0.83 2.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Xbrane Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Xbrane Biopharma has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Xbrane Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Xbrane Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Xbrane Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XBRANE BTA Health

 How is Xbrane Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Xbrane Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Xbrane Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Xbrane Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Xbrane Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Xbrane Biopharma Company Filings, last reported 3 months ago.

OM:XBRANE BTA Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 83.07 45.60 100.97
2018-09-30 114.53 45.75 64.31
2018-06-30 55.60 35.90 19.26
2018-03-31 83.63 21.03 18.93
2017-12-31 88.41 1.12 7.90
2017-09-30 105.56 3.92 23.62
2017-06-30 105.57 4.09 32.37
2017-03-31 96.76 4.15 22.46
2016-12-31 113.90 1.73 31.34
2016-09-30 118.00 0.00 43.92
2016-06-30 126.49 0.00 56.69
2016-03-31 132.67 0.00 68.61
2015-12-31 47.51 4.06 2.69
2015-09-30 55.99 0.00 2.81
2014-12-31 6.30 0.00 6.20
2013-12-31 8.69 0.00 8.88
2012-12-31 0.09 0.00 0.37
  • Xbrane Biopharma's level of debt (54.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 54.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Xbrane Biopharma has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Xbrane Biopharma has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -26.6% per year.
X
Financial health checks
We assess Xbrane Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Xbrane Biopharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XBRANE BTA Dividends

 What is Xbrane Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Xbrane Biopharma dividends. Estimated to be 0% next year.
If you bought SEK2,000 of Xbrane Biopharma shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Xbrane Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Xbrane Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:XBRANE BTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.8%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 246 Stocks 3.5%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.2%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.9%
Sweden Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:XBRANE BTA Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Xbrane Biopharma has not reported any payouts.
  • Unable to verify if Xbrane Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Xbrane Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Xbrane Biopharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Xbrane Biopharma's dividends in 3 years as they are not expected to pay a notable one for Sweden.
X
Income/ dividend checks
We assess Xbrane Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Xbrane Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Xbrane Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XBRANE BTA Management

 What is the CEO of Xbrane Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Martin Åmark
AGE 38
TENURE AS CEO 4.3 years
CEO Bio

Mr. Martin Åmark serves as the Head of Investor Relation since February 14, 2019 and also serves as Chief Executive Officer of Xbrane Biopharma AB (publ). Mr. Åmark has 8 years of experience from Bain & Co as a Management Consultant. At Bain, he worked mainly with M&A, strategy and organisation with Nordic clients across multiple industries, including life science and pharmaceuticals. Mr. Åmark holds a M Sc. in industrial engineering and management from Linköping Institute of Technology and an MBA from INSEAD.

CEO Compensation
  • Insufficient data for Martin to compare compensation growth.
  • Insufficient data for Martin to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the Xbrane Biopharma management team in years:

4.3
Average Tenure
37
Average Age
  • The tenure for the Xbrane Biopharma management team is about average.
Management Team

Martin Åmark

TITLE
CEO & Head of Investor Relation
AGE
38
TENURE
4.3 yrs

Samuel Wagner

TITLE
Co-Founder & Member of Scientific Advisory Board
TENURE
11.3 yrs

Susanna Helgesen

TITLE
Chief Financial Officer
AGE
33
TENURE
1.9 yrs

Siavash Bashiri

TITLE
COO, Head of Biosimilars & Deputy CEO
AGE
35

David Vikström

TITLE
Chief Technology Officer
AGE
41
TENURE
5.3 yrs

Paolo Sarmientos

TITLE
Interim Head of Production & Head of Controlled Release Generics
AGE
61

Dina Jurman

TITLE
Head of Clinical Affairs
AGE
36
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Xbrane Biopharma board of directors in years:

2.8
Average Tenure
60.5
Average Age
  • The average tenure for the Xbrane Biopharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Anders Tullgren

TITLE
Chairman
AGE
57
TENURE
1 yrs

Samuel Wagner

TITLE
Co-Founder & Member of Scientific Advisory Board

Saeid Esmaeilzadeh

TITLE
Director
AGE
44
TENURE
1.3 yrs

Peter Edman

TITLE
Director
AGE
64
TENURE
4.3 yrs

Alessandro Sidoli

TITLE
Director
AGE
59
TENURE
2.8 yrs

Gunnar Von Heijne

TITLE
Member of Scientific Advisory Board

Björn Nilsson

TITLE
Member of Scientific Advisory Board
AGE
62

Joen Luirink

TITLE
Member of Scientific Advisory Board

David Drew

TITLE
Member of Scientific Advisory Board

Maris Hartmanis

TITLE
Director
AGE
65
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess Xbrane Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Xbrane Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XBRANE BTA News

Simply Wall St News

XBRANE BTA Company Info

Description

Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Its lead product candidates under development include Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes related macular edema, diabetic retinopathy, and retinal vein occlusion; and Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma. The company is headquartered in Solna, Sweden.

Details
Name: Xbrane Biopharma AB (publ)
XBRANE BTA
Exchange: OM
Founded:
SEK371,328,532
8,307,126
Website: http://www.xbrane.com
Address: Xbrane Biopharma AB (publ)
Banvaktsvägen 22,
Solna,
Stockholm County, 171 48,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM XBRANE Share Capital OMX Nordic Exchange Stockholm SE SEK 03. Feb 2016
OM XBRANE BTA SHS OMX Nordic Exchange Stockholm SE SEK 13. Mar 2019
Number of employees
Current staff
Staff numbers
27
Xbrane Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/15 22:53
End of day share price update: 2019/04/12 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.